Akebia Therapeutics (AKBA) Gains from Investment Securities (2015 - 2025)

Akebia Therapeutics (AKBA) has 11 years of Gains from Investment Securities data on file, last reported at -$2.3 million in Q4 2025.

• Gains from Investment Securities for Q4 2025 came in at -$2.3 million, down 268.18% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.3 million (up 1868.48% YoY), and the FY2025 annual result was $3.1 million, changed N/A from the prior year.
• Gains from Investment Securities declined to -$2.3 million in Q4 2025 per AKBA's latest filing, from -$1.5 million in the prior quarter.
• Over five years, Gains from Investment Securities peaked at $26.7 million in Q4 2022 and troughed at -$11.0 million in Q3 2022.
• A 5-year average of -$96166.7 and a median of -$1.2 million in 2021 frame the typical range for Gains from Investment Securities.
• The sharpest annual moves came in 2021 and 2022: Gains from Investment Securities plunged 25245.45% in 2021, then soared 2917.55% in 2022.
• A 5-year view of Gains from Investment Securities shows it stood at -$946000.0 in 2021, then soared by 2917.55% to $26.7 million in 2022, then tumbled by 130.67% to -$8.2 million in 2023, then soared by 116.45% to $1.3 million in 2024, then tumbled by 268.18% to -$2.3 million in 2025.
• Business Quant data shows AKBA's Gains from Investment Securities at -$2.3 million in Q4 2025, -$1.5 million in Q3 2025, and $7.0 million in Q2 2025.